Stay updated on Radiotherapy and Pembrolizumab in Metastatic HNSCC Clinical Trial
Sign up to get notified when there's something new on the Radiotherapy and Pembrolizumab in Metastatic HNSCC Clinical Trial page.

Latest updates to the Radiotherapy and Pembrolizumab in Metastatic HNSCC Clinical Trial page
- Check5 days agoNo Change Detected
- Check12 days agoNo Change Detected
- Check19 days agoChange DetectedThe page's revision tag has been updated to v3.5.4. The previous revision tag v3.5.3 was removed.SummaryDifference0.1%

- Check26 days agoNo Change Detected
- Check41 days agoChange DetectedThe page’s display version/revision indicator was updated from v3.5.0 to v3.5.3, reflecting a site/release stack change rather than any modification to the underlying study information.SummaryDifference0.1%

- Check69 days agoChange DetectedAdded detailed definitions for response criteria (iRECIST/RECIST) and endpoints (CR, PR, SD, PD) under Outcome Measures. Included an external resource reference (Genetic and Rare Diseases Information Center) related to head and neck cancer terminology.SummaryDifference0.8%

- Check77 days agoChange DetectedRevision updated from v3.4.3 to v3.5.0. No user-visible changes to the Study Details page are indicated.SummaryDifference0.1%

- Check84 days agoChange DetectedUpdated the IMPORTANCE trial entry with slow recruitment and termination status, along with a 'Results Posted' update. Added detailed study plan information and key dates.SummaryDifference3%

- Check91 days agoChange DetectedRevision tag updated from v3.4.2 to v3.4.3 on the page.SummaryDifference0.1%

Stay in the know with updates to Radiotherapy and Pembrolizumab in Metastatic HNSCC Clinical Trial
Enter your email address, and we'll notify you when there's something new on the Radiotherapy and Pembrolizumab in Metastatic HNSCC Clinical Trial page.